Randomized Controlled Trial of Valganciclovir for Asymptomatic Cytomegalovirus Infected Hearing Impaired Infants
The overall goal of this study is to determine the clinical benefit and safety of antiviral therapy for asymptomatic congenital cytomegalovirus (cCMV) infected hearing-impaired infants. We will conduct a multi-center double-blind randomized placebo-controlled trial to determine whether hearing-impaired infants with asymptomatic cCMV have better hearing and language outcomes if they receive valganciclovir antiviral treatment. We will also determine the safety of antiviral valganciclovir therapy for asymptomatic cCMV-infected hearing impaired infants. This study will be unique in that the cohort enrolled will only include hearing-impaired infants with asymptomatic cCMV. Aim 1: Test the hypothesis that asymptomatic CMV-infected hearing impaired infants treated with antiviral valganciclovir will have better hearing and language outcomes compared with untreated CMV-infected hearing impaired infants. Aim 2: Evaluate the safety of antiviral valganciclovir therapy for asymptomatic CMV-infected hearing impaired infants. Aim 3: Evaluate the pharmacokinetics (pK) of valganciclovir using pharmacometrics modeling to develop a population pK model.
Randomized Controlled Trial of Valganciclovir for Asymptomatic Cytomegalovirus Infected Hearing Impaired Infants: ValEAR Trial
Cytomegalovirus (CMV) can be transmitted from the mother to the fetus and is a leading cause of sensorineural hearing loss (SNHL), which is a condition where the inner ear is unable to convert sound into nerve impulses to the brain. This hearing loss and its detrimental effect on language development contribute nearly $4 billion annually to the health care costs in the U.S. Unlike other types of SNHL, CMV induced hearing loss can be treated. Several clinical trials have demonstrated that antiviral therapy may prevent progressive hearing loss if administered early in life for severely affected (symptomatic CMV) infants. These promising findings have given rise to a debate regarding the best method for identifying and treating the more numerous asymptomatic CMV-infected infants.
One approach is to conduct universal newborn hearing screens, and then do CMV diagnostic testing only on the infants who fail the hearing screen. This targeted approach should identify those infants at greatest risk of developing progressive hearing loss and consequent communicative difficulties. Utah is the first state to mandate this approach whereby infants under three weeks of age who fail their newborn hearing screening undergo CMV testing. In this trial, the hearing screen targeted approach will be used to identify patients eligible for participation in a double blind placebo controlled randomized clinical trial of antiviral valganciclovir therapy. The results of this trial will inform public policy, potentially shift our current clinical practice regarding pediatric hearing loss evaluation, and potentially offer a therapeutic option to asymptomatic CMV-infected infants with SNHL.
Cmv Congenital CMV Congenital Cmv SNHL Sensorineural Hearing Loss valganciclovir Ganciclovir
You can join if…
Open to people ages up to 5 months
- Age less than 6 months at the time of randomization; AND
- Less than or equal to 37 weeks gestational age at birth; AND
- Positive congenital CMV by urine culture or polymerase chain reaction test(PCR), OR saliva culture or PCR followed by confirmatory urine PCR by 21 days of age, OR urine culture or PCR after 21 days of age followed by newborn dry blood spot PCR; AND
- Failed hearing screen, with confirmed sensorineural hearing loss (SNHL) by auditory brainstem response (ABR) testing.
You CAN'T join if...
- Imminent demise; OR
- Lack of commitment to aggressive care; OR
- Significant gastrointestinal disorders (e.g., eosinophilic esophagitis, ulcerative colitis); OR
- Significant hematologic disorders (e.g., hemophilia, leukemia, sickle cell anemia); OR
- Significant renal disorders (e.g., nephrotic syndrome); OR
- Receiving other antiviral medications or immune globulin therapy; OR
- Receiving other investigational drugs; OR
- Breast feeding from a mother receiving antiviral or immunosuppressive medication; OR
- Other known cause contributing to SNHL (e.g., meningitis, aminoglycoside ototoxicity);OR
- Bilateral profound SNHL or auditory neuropathy spectrum disorder; OR
- Evidence of intracranial calcification; OR
- Evidence of hydrocephalus; OR
- Microcephaly; OR
- Presence of petechiae; OR
- Intrauterine growth retardation; OR
- Hepatitis; OR
- Parent or guardian unable to speak English or Spanish; OR
- Patient unable to attend follow-up hearing and developmental assessment at 12 months of age.
- UCSF Benioff Children's Hospital not yet accepting patients
San Francisco, California, 94158, United States
- Lucile Packard Children's Hospital not yet accepting patients
Palo Alto, California, 94304, United States
- not yet accepting patients
- Start Date
- Completion Date
- Albert Park
- Phase 3
- Study Type
- Last Updated
- April 1, 2017
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT03107871.